Literature DB >> 26265697

GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells.

Brent H Koehn1, Petya Apostolova2, Jessica M Haverkamp3, Jeffrey S Miller4, Valarie McCullar4, Jakub Tolar1, David H Munn5, William J Murphy6, Willie June Brickey7, Jonathan S Serody7, Dmitry I Gabrilovich8, Vincenzo Bronte9, Peter J Murray3, Jenny P-Y Ting7, Robert Zeiser10, Bruce R Blazar1.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are a naturally occurring immune regulatory population associated with inhibition of ongoing inflammatory responses. In vitro generation of MDSCs from bone marrow has been shown to enhance survival in an acute model of lethal graft-versus-host disease (GVHD). However, donor MDSC infusion only partially ameliorates GVHD lethality. In order to improve the potential therapeutic benefit and ultimately survival outcomes, we set out to investigate the fate of MDSCs after transfer in the setting of acute GVHD (aGVHD). MDSCs transferred to lethally irradiated recipients of allogeneic donor hematopoietic grafts are exposed to an intense inflammatory environment associated with aGVHD, which we now show directly undermines their suppressive capacity. Under a conditioning regimen and GVHD inflammatory settings, MDSCs rapidly lose suppressor function and their potential to inhibit GVHD lethality, which is associated with their induced conversion toward a mature inflammasome-activated state. We find even brief in vitro exposure to inflammasome-activating mediators negates the suppressive potential of cultured murine and human-derived MDSCs. Consistent with a role for the inflammasome, donor MDSCs deficient in the adaptor ASC (apoptosis-associated speck-like protein containing a CARD), which assembles inflammasome complexes, conferred improved survival of mice developing GVHD compared with wild-type donor MDSCs. These data suggest the use of MDSCs as a therapeutic approach for preventing GVHD and other systemic inflammatory conditions will be more effective when combined with approaches limiting in vivo MDSC inflammasome activation, empowering MDSCs to maintain their suppressive potential.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26265697      PMCID: PMC4582338          DOI: 10.1182/blood-2015-03-634691

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

Review 1.  The inflammasomes.

Authors:  Kate Schroder; Jurg Tschopp
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  The inflammasomes: guardians of the body.

Authors:  Fabio Martinon; Annick Mayor; Jürg Tschopp
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

Review 3.  Myeloid-derived suppressor cell heterogeneity and subset definition.

Authors:  Elisa Peranzoni; Serena Zilio; Ilaria Marigo; Luigi Dolcetti; Paola Zanovello; Susanna Mandruzzato; Vincenzo Bronte
Journal:  Curr Opin Immunol       Date:  2010-02-17       Impact factor: 7.486

4.  TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection.

Authors:  Patricia A Taylor; Michael J Ehrhardt; Christopher J Lees; Angela Panoskaltsis-Mortari; Arthur M Krieg; Arlene H Sharpe; William J Murphy; Jonathan S Serody; Hiroaki Hemmi; Shizuo Akira; Robert B Levy; Bruce R Blazar
Journal:  Blood       Date:  2008-07-09       Impact factor: 22.113

Review 5.  Myeloid-derived suppressor cells: linking inflammation and cancer.

Authors:  Suzanne Ostrand-Rosenberg; Pratima Sinha
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

6.  Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells.

Authors:  Zuping Zhou; Deborah L French; Ge Ma; Samuel Eisenstein; Ying Chen; Celia M Divino; Gordon Keller; Shu-Hsia Chen; Ping-Ying Pan
Journal:  Stem Cells       Date:  2010-03-31       Impact factor: 6.277

7.  Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells.

Authors:  Keli L Hippen; Paul Harker-Murray; Stephen B Porter; Sarah C Merkel; Aryel Londer; Dawn K Taylor; Megan Bina; Angela Panoskaltsis-Mortari; Pablo Rubinstein; Nico Van Rooijen; Tatiana N Golovina; Megan M Suhoski; Jeffrey S Miller; John E Wagner; Carl H June; James L Riley; Bruce R Blazar
Journal:  Blood       Date:  2008-07-21       Impact factor: 22.113

Review 8.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

Review 9.  Immunological and inflammatory functions of the interleukin-1 family.

Authors:  Charles A Dinarello
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

10.  A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.

Authors:  Rebecca C Coll; Avril A B Robertson; Jae Jin Chae; Sarah C Higgins; Raúl Muñoz-Planillo; Marco C Inserra; Irina Vetter; Lara S Dungan; Brian G Monks; Andrea Stutz; Daniel E Croker; Mark S Butler; Moritz Haneklaus; Caroline E Sutton; Gabriel Núñez; Eicke Latz; Daniel L Kastner; Kingston H G Mills; Seth L Masters; Kate Schroder; Matthew A Cooper; Luke A J O'Neill
Journal:  Nat Med       Date:  2015-02-16       Impact factor: 53.440

View more
  60 in total

Review 1.  Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation.

Authors:  Brent H Koehn; Bruce R Blazar
Journal:  J Leukoc Biol       Date:  2017-02-01       Impact factor: 4.962

2.  Adoptive Cell Therapy with Tregs to Improve Transplant Outcomes: The Promise and the Stumbling Blocks.

Authors:  Mohamed B Ezzelarab; Angus W Thomson
Journal:  Curr Transplant Rep       Date:  2016-10-25

Review 3.  Recent advances in myeloid-derived suppressor cell biology.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani; Ammar Daoud
Journal:  Front Med       Date:  2020-09-02       Impact factor: 4.592

4.  IAPs protect host target tissues from graft-versus-host disease in mice.

Authors:  Tomomi Toubai; Corinne Rossi; Katherine Oravecz-Wilson; Chen Liu; Cynthia Zajac; Shin-Rong Julia Wu; Yaping Sun; Hideaki Fujiwara; Hiroya Tamaki; Daniel Peltier; Mary Riwes; Israel Henig; Stuart Brabbs; Colin S Duckett; Shaomeng Wang; Pavan Reddy
Journal:  Blood Adv       Date:  2017-08-16

5.  We didn't start the fire, MDSC inflammasome signaling in GVHD.

Authors:  Nataliya Prokopenko Buxbaum
Journal:  Blood       Date:  2019-11-07       Impact factor: 22.113

6.  Myeloid-derived Suppressor Cells Are Necessary for Development of Pulmonary Hypertension.

Authors:  Andrew J Bryant; Vinayak Shenoy; Chunhua Fu; George Marek; Kyle J Lorentsen; Erica L Herzog; Mark L Brantly; Dorina Avram; Edward W Scott
Journal:  Am J Respir Cell Mol Biol       Date:  2018-02       Impact factor: 6.914

Review 7.  Inflammasomes and IL-1 biology in the pathogenesis of allograft dysfunction.

Authors:  S Samuel Weigt; Vyacheslav Palchevskiy; John A Belperio
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

Review 8.  Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies.

Authors:  Peng-Fei Wang; Si-Ying Song; Ting-Jian Wang; Wen-Jun Ji; Shou-Wei Li; Ning Liu; Chang-Xiang Yan
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

9.  Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  Blood       Date:  2016-03-18       Impact factor: 22.113

Review 10.  Regulation of cellular immunity by activating transcription factor 4.

Authors:  Debasmita Mukherjee; Lena S Bercz; Molly A Torok; Thomas A Mace
Journal:  Immunol Lett       Date:  2020-09-28       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.